Merz North America Congratulates Glenn Block on His Induction into the Canadian Healthcare Marketing Hall of Fame Glenn Block, President & General Manager of Merz Pharma Canada, Ltd., to be recognized for his contributions to the Canadian healthcare community Business Wire GREENSBORO, N.C. -- April 10, 2013 Merz North America (affiliate of Merz Pharma Group) congratulates Glenn Block, President and General Manager of Merz Pharma Canada, Ltd., who has been selected for induction into the Canadian Healthcare Marketing Hall of Fame. Block joined Merz in August 2007 and is responsible for all aspects of the company’s strategy and operations in Canada. He also holds the distinction of having built the Canadian organization from the ground up. "Glenn has a proven track record in the development and commercialization of pharmaceutical and OTC/OTX products in Canada, and he has made immense contributions to the growth of our business in North America. His induction into the Canadian Healthcare Marketing Hall of Fame is truly an appropriate recognition of the impact he continues to have, not only on our business, but within the Canadian healthcare community as a whole,” said Bill Humphries, president & CEO of Merz North America. The Canadian Healthcare Marketing Hall of Fame was established in 2006 in conjunction with the National Pharmaceutical Congress, and the induction ceremony will take place today, April 10, 2013 at the close of the 7th National Pharmaceutical Congress in Toronto, Ontario. According to the Chronicle Group of Companies, which organizes the event, inductees are chosen based on distinctive contributions to the Canadian healthcare industry: “The awards were established to honor healthcare marketers who have contributed to our avocation and are an inspiration to others. These honorees were chosen from this field of deserving candidates, but stand for, in the view of the selection committee, a representative cross-section of the qualities that make our business unique and fulfilling.^1” “I am honored to be joining this cohort of innovative and inspiring healthcare marketing professionals. Any success I have achieved in this industry is due to a few individuals who have taken a chance on me during my career, as well as to the great teams I have had the fortune to work with. I see this award as representative of the status that Merz has achieved in the Canadian healthcare community in a very short time, and I look forward to the continued growth and success of our business here and across North America,” said Glenn Block, President and General Manager, Merz Pharma Canada, Ltd. Block has over 20 years of experience in the pharmaceutical industry, with most of those years focused on the development and marketing of neurotoxins in North America. Prior to joining Merz, he held senior-level marketing positions with Biogen Idec Canada and Allergan, Inc. Block holds an Honors Bachelor of Commerce degree from Queen’s University in Kingston, Ontario. He is based at Merz offices in Toronto, Ontario. About Merz North America Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in medical and aesthetic dermatology, and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients’ lives. For more than 100 years, the development of our products has been based on Merz‘s commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses, and they have assumed a leading role in the field of Alzheimer’s disease research. Founded in 1908, Merz Pharma Group is a privately owned company headquartered in Frankfurt, Germany. Strategic Canadian brands include Radiesse^® Volumizing Filler, Xeomin^®, and Mederma^®. For more information about Merz Pharma Canada, Ltd. or their products, please visit www.merzcanada.com. For information regarding Merz products and operations in the United States, please visit www.merzusa.com or www.merzaesthetics.com/en-US/. IMPORTANT SAFETY INFORMATION for XEOMIN^®, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of XEOMIN^® (incobotulinumtoxinA) for injection, for intramuscular use, and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses. Please see Full Prescribing Information, including Medication Guide for more information. CONTRAINDICATIONS XEOMIN^® is contraindicated in patients with a known hypersensitivity to the active substance botulinum toxin type A or to any of the components in the formulation and in the presence of infection at the proposed injection site(s), as injection could lead to severe local or disseminated infection. WARNINGS AND PRECAUTIONS *The potency units of XEOMIN^® are not interchangeable with other preparations of botulinum toxin products. Therefore, units of biological activity of XEOMIN^® cannot be compared to or converted into units of any other botulinum toxin products. *Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN^® should be discontinued and appropriate medical therapy immediately instituted. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. *Treatment with XEOMIN^® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagiaThese reactions can occur within hours to weeks after injection with botulinum toxin. [See Boxed Warning]. *Cervical Dystonia: Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia. *Blepharospasm: Injection of XEOMIN^® into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections. *Glabellar Lines: Do not exceed the recommended dosage and frequency of administration of XEOMIN^®. In order to reduce the complication of ptosis the following steps should be taken: *Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. *Corrugator injections should be placed at least 1 cm above the bony supraorbital ridge. *Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN^®. *XEOMIN^® contains albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases or CJD have ever been reported for albumin. ADVERSE REACTIONS Cervical Dystonia: The most commonly observed adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN^® 120 Units and XEOMIN^® 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%, 15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%). Blepharospasm: The most common adverse reactions (incidence ≥10% of patients and twice the rate of placebo) for XEOMIN^® were eyelid ptosis (19%), dry mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%). Glabellar Lines: The most common adverse reaction (incidence ≥ 2% of patients and greater than placebo) for XEOMIN^® was Headache (5.4%). DRUG INTERACTIONS Concomitant treatment of XEOMIN^® and aminoglycoside antibiotics, spectinomycin, or other agents that interfere with neuromuscular transmission (e.g., tubocurarine-like agents), or muscle relaxants, should be observed closely because the effect of XEOMIN may be potentiated. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. USE IN PREGNANCY Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. XEOMIN^® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. PEDIATRIC USE The safety and effectiveness of XEOMIN^® in patients less than 18 years of age have not been established. Please see Full Prescribing Information for more information on XEOMIN^® (incobotulinumtoxinA) for injection, for intramuscular use, including complete Boxed WARNING, available at www.Xeomin.com and at www.XeominAesthetic.com. Botox^® is a registered trademark of Allergan. ^1 Source: National Pharmaceutical Congress Contact: Merz North America Mariana Smith, 336-217-2636 Corporate Communications firstname.lastname@example.org
Merz North America Congratulates Glenn Block on His Induction into the Canadian Healthcare Marketing Hall of Fame
Press spacebar to pause and continue. Press esc to stop.